Your browser doesn't support javascript.
loading
Uptake of hepatitis C virus treatment in a multi-state Medicaid population, 2013-2017.
Clements, Karen M; Kunte, Parag S; Clark, Melissa A; Gurewich, Deborah; Greenwood, Bonnie C; Sefton, Laura; Pratt, Carter; Person, Sharina D; Wessolossky, Miryea A.
Afiliación
  • Clements KM; Commonwealth Medicine, University of Massachusetts Chan Medical School, Shrewsbury, Massachusetts, USA.
  • Kunte PS; Commonwealth Medicine, University of Massachusetts Chan Medical School, Shrewsbury, Massachusetts, USA.
  • Clark MA; Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
  • Gurewich D; Center for Healthcare Organization and Implementation Research, VA Boston Health Care System Jamaica Plain Campus, Boston, Massachusetts, USA.
  • Greenwood BC; Commonwealth Medicine, University of Massachusetts Chan Medical School, Shrewsbury, Massachusetts, USA.
  • Sefton L; Commonwealth Medicine, University of Massachusetts Chan Medical School, Shrewsbury, Massachusetts, USA.
  • Pratt C; Commonwealth Medicine, University of Massachusetts Chan Medical School, Shrewsbury, Massachusetts, USA.
  • Person SD; Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
  • Wessolossky MA; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Health Serv Res ; 57(6): 1312-1320, 2022 12.
Article en En | MEDLINE | ID: mdl-35466398
ABSTRACT

OBJECTIVE:

To examine trends in the direct acting antiviral (DAA) uptake in a multi-state Medicaid population with hepatitis C virus (HCV) prior to and after ledipasvir/sofosbuvir (LDV/SOF) approval and changes in prior authorization (PA) requirements. DATA SOURCES Analyses utilized enrollment, medical, and pharmacy claims in four states, December 2013-December 2017. STUDY

DESIGN:

An interrupted time series examined trends in uptake (1+ claim for a DAA) before and after two events LDV/SOV approval (October 2014) and lifting of PA requirements for 40% of members (July 2016). Analyses were also performed in subgroups defined by the number and dates of change in PA requirements in members' Medicaid plans. DATA COLLECTION/EXTRACTION

METHODS:

Members aged 18-64 years with an ICD code for HCV were included in the sample from diagnosis date until treatment initiation or Medicaid disenrollment. PRINCIPAL

FINDINGS:

The annual sample size ranged from 38,302 to 45,005 with approximately 30% ages 18-34 years and 40% female. In December 2013, 0.08% was treated, rising to 0.74% in December 2017 (p < 0.001). Uptake increased from 0.34%/month in October 2014 to 0.70%/month after LDV/SOF approval, (p < 0.001), and increased relative to the pre-LDV/SOV trend through June 2016 (p = 0.04). Uptake increased to 1.18%/month after PA change, (p < 0.001) and remained flat through 2017 (p = 0.64). Cumulatively, 20.1% were treated by December 2017. In plans with few/no requirements through 2017, uptake increased to 1.19%/month after LDV/SOF approval (p < 0.001) and remained flat through 2017 (p = 0.11), with 22.2% cumulatively treated. Among plans that lifted PA requirements from three to zero in mid-2016, uptake did not increase after LDV/SOF approval (p = 0.36) but did increase to 1.41%/month (p < 0.001) after PA change, with 18.1% cumulatively treated.

CONCLUSIONS:

HCV Treatment increased through 2017. LDV/SOF approval and lifting PA requirements led to an increase in uptake followed by flat monthly utilization. Cumulative uptake was higher in plans with few/no PA requirements relative to those with three requirements through mid-2016.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hepatitis C / Hepatitis C Crónica Límite: Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Health Serv Res Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hepatitis C / Hepatitis C Crónica Límite: Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Health Serv Res Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos